๐ฐ Iagnostics News
Page 12 - Iagnostics News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Iagnostics. Real-time updates on events, politics, business and more.
October 17, 2023
Dublin, Oct. 17, 2023 (GLOBE NEWSWIRE) -- In a world where breast cancer awareness is more critical than ever, a groundbreaking research report, titled...
October 16, 2023
Dublin, Oct. 16, 2023 (GLOBE NEWSWIRE) -- The
October 14, 2023
A team of investigators from the UCLA Jonsson Comprehensive Cancer Center and the UCLA School of Dentistry received a five-year $4.6 million grant from the National Cancer Institute to develop and improve liquid biopsy technologies for the early detection of lung cancer -; the leading cause of cancer death in both men and women in the U.S.
October 12, 2023
SelectScience is a scientific publication for product news, application notes, events, videos and laboratory product reviews.
October 11, 2023
High-grade serous ovarian carcinoma (HGSOC) is the most common type of ovarian cancer. It is also the most lethal form, in part because clinicians do not have effective ways to screen women for it during the cancer's early stages, when it's easiest to treat.
October 10, 2023
Liquid biopsies are blood tests that can serially measure circulating tumor DNA (cell-free DNA that is shed into the bloodstream by dying cancer cells).
October 10, 2023
Incorporating RNA sequencing provides better diagnostics to enable a more complete understanding of disease biology...
October 9, 2023
COVID-19 disrupts TB diagnostic services in South Africa's primary health clinics, highlighting the need for robust systems resilient to future pandemics.
October 9, 2023
We spoke to Professor Janet Hemingway, founding Director of iiCON and Professor of Tropical Medicine atย Liverpool School of Tropical Medicine.
October 6, 2023
Bio-Rad Laboratories, a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of six antibodies specific to dupilumab (Dupixent) and the addition of new evolocumab (Repatha), ipilimumab (Yervoy), and secukinumab (Cosentyx) antibodies.